LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Heron Therapeutics Inc

Chiusa

SettoreSettore sanitario

1.29 -1.53

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.29

Massimo

1.34

Metriche Chiave

By Trading Economics

Entrata

-5M

-2.4M

Vendite

-1.7M

37M

Margine di Profitto

-6.401

Dipendenti

122

EBITDA

-5.3M

-1.6M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+246.15% upside

Dividendi

By Dow Jones

Utili prossimi

11 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-60M

207M

Apertura precedente

2.82

Chiusura precedente

1.29

Notizie sul Sentiment di mercato

By Acuity

50%

50%

156 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Heron Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 set 2025, 23:37 UTC

Azioni calde

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 set 2025, 20:41 UTC

Utili

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 set 2025, 20:30 UTC

Utili

GameStop 2Q Sales, Profit Rise

9 set 2025, 23:19 UTC

Discorsi di Mercato

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 set 2025, 21:35 UTC

Utili

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 21:32 UTC

Utili

Oracle's Backlog Swells With Big Customer Deals -- Update

9 set 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 set 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 set 2025, 20:26 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:23 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:12 UTC

Utili

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 set 2025, 20:10 UTC

Utili

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 set 2025, 20:10 UTC

Utili

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 set 2025, 20:08 UTC

Utili

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 set 2025, 20:07 UTC

Utili

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Software Revenue $5.72B >ORCL

9 set 2025, 20:06 UTC

Utili

Synopsys 3Q Adj EPS $3.39 >SNPS

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Rev $14.93B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q EPS $1.01 >ORCL

9 set 2025, 20:05 UTC

Utili

Synopsys 3Q EPS $1.50 >SNPS

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Services Revenue $1.35B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Adj EPS $1.47 >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Hardware Revenue $670M >ORCL

Confronto tra pari

Modifica del prezzo

Heron Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

246.15% in crescita

Previsioni per 12 mesi

Media 4.5 USD  246.15%

Alto 6 USD

Basso 3 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Heron Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.0001 / 2.42Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

156 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat